FY2025 Earnings Estimate for ResMed Issued By Zacks Research

ResMed Inc. (NYSE:RMD) – Investment analysts at Zacks Research increased their FY2025 earnings estimates for shares of ResMed in a research report issued to clients and investors on Thursday, February 27th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $9.36 per share for the year, up from their previous estimate of $9.35. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.40 EPS, Q1 2026 earnings at $2.30 EPS, Q2 2026 earnings at $2.40 EPS, FY2026 earnings at $9.69 EPS, Q1 2027 earnings at $2.50 EPS, Q2 2027 earnings at $2.61 EPS and FY2027 earnings at $10.64 EPS.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

RMD has been the topic of a number of other reports. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research report on Friday, January 31st. The Goldman Sachs Group began coverage on ResMed in a report on Thursday, January 16th. They set a “buy” rating for the company. UBS Group raised ResMed from a “hold” rating to a “strong-buy” rating in a report on Friday, January 31st. JPMorgan Chase & Co. increased their price target on ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Finally, KeyCorp increased their price target on ResMed from $266.00 to $280.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have given a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $244.73.

ResMed Stock Down 0.2 %

RMD stock opened at $233.12 on Monday. The company’s 50 day moving average price is $237.10 and its 200 day moving average price is $239.99. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. ResMed has a fifty-two week low of $172.19 and a fifty-two week high of $263.05. The firm has a market capitalization of $34.24 billion, a price-to-earnings ratio of 27.52, a PEG ratio of 1.53 and a beta of 0.70.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Thursday, February 13th. ResMed’s dividend payout ratio is currently 25.03%.

Insider Activity

In other news, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total value of $491,300.00. Following the completion of the transaction, the director now owns 81,218 shares in the company, valued at $19,951,201.70. This trade represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael J. Farrell sold 8,009 shares of the firm’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $236.77, for a total value of $1,896,290.93. Following the completion of the transaction, the chief executive officer now owns 455,472 shares of the company’s stock, valued at approximately $107,842,105.44. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,073 shares of company stock worth $2,887,326 over the last 90 days. 0.71% of the stock is currently owned by corporate insiders.

Institutional Trading of ResMed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. True Wealth Design LLC increased its position in ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 110 shares in the last quarter. Colonial Trust Co SC increased its position in ResMed by 6,250.0% during the 4th quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 125 shares in the last quarter. Optiver Holding B.V. purchased a new stake in ResMed during the 4th quarter worth about $33,000. Ashton Thomas Securities LLC purchased a new stake in ResMed during the 3rd quarter worth about $34,000. Finally, Itau Unibanco Holding S.A. increased its position in ResMed by 1,000.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.